Hyaluronan--a review of the recent patent literature.
IDrugs : the investigational drugs journal
confidence
Key findings
Review of hyaluronan patent literature; no clinical or biological endpoints reported. Not relevant to N-Acetyl Cysteine.
View source on PubMed (PMID 16107939) ↗
- Sample size
- N/A
- Population
- Not applicable (patent literature review)
- Dosing
- N/A
- Duration
- N/A
- Route
- N/A
- Blinding
- not_reported
- Controls
- not_reported
- Drug class
- amino acid derivative
Full abstract
A review of patent literature surrounding the use of hyaluronan (HA) and its derivatives, or agents capable of modulating endogenous levels, is presented. Indications are many and varied and include arthritis, abnormal wound healing, neoplasia, prevention of surgical adhesions and dermatological disorders. In many cases, it is the physicochemical and biological properties of HA itself that have been exploited. For example, HA and/or its derivatives have been suggested as a synovial fluid replacement, a vehicle for topical application of drugs, a matrix for sustained drug release and a putative drug delivery system (targeting HA receptors at sites of pathology). In each of these examples, the lack of toxicity of HA and its biocompatability are important considerations.